Comparative Analysis of Myostatin Inhibitors

Mechanisms of Action

Myostatin, a protein that inhibits muscle growth, is the target of every agent on this page. In cell culture it slows protein synthesis in muscle cells, and blocking it is meant to promote muscle hypertrophy. Our myostatin inhibitors overview covers the pathway in more depth.

Key inhibitor types

• Follistatin: naturally occurring glycoprotein that binds and neutralizes myostatin. Human work uses gene therapy; see our follistatin research notes
• ACE-031: synthetic decoy receptor (soluble ActRIIB) that captures myostatin and related proteins; see the ACE-031 overview
• Antibodies: monoclonal antibodies against myostatin (stamulumab, trevogrumab), its latent precursor (apitegromab), or its receptor (bimagrumab, ActRII)
• Gene Silencing: experimental approaches using siRNA or antisense oligonucleotides

Comparative Efficacy

As of October 2026, apitegromab (Isembyld) is approved only for SMA, in patients aged 2 and older already on an SMN2-targeted treatment. The newer obesity trials test whether these drugs protect muscle during GLP-1 weight loss. In BELIEVE (507 adults, Nature Medicine 2026), lean mass fell 4.7% to 6.9% at 48 weeks on semaglutide alone versus 0.8% to 2.3% with bimagrumab added. In COURAGE, reported October 1, 2026, lean mass fell 7.3% on semaglutide alone and 4.2% to 5.8% with lower-dose trevogrumab, which didn't add weight loss.

Benefits

What the human data show so far:

• Increased muscle mass: preserved or increased lean mass in the SMA and obesity trials
• Improved muscle strength: untested in healthy people; stamulumab's trial found no strength change, though it wasn't powered to find one
• Motor function in SMA: 34.2% on apitegromab improved meaningfully at one year, versus 13.5% on placebo (FDA, ages 2-12)
• Enhanced recovery: faster regeneration after muscle damage is mostly an animal-study finding

Risks and Ethical Concerns

• Bleeding abnormalities: nosebleeds and gum bleeding halted ACE-031's Duchenne trial in 2011
• Fractures: the apitegromab label warns of serious fractures
• Cardiovascular effects: potential impacts on heart muscle remain theoretical; we found no human signal
• Tendon/ligament concerns: often repeated, but untested in people
• Unknown long-term effects: the longest obesity data run 72 weeks
• Sport: as of October 2026, WADA's 2026 Prohibited List bans all of these at all times under S4.3

What we still don't know

No trial has tested these drugs in healthy, trained people, or shown that preserved lean mass during GLP-1 treatment improves function. Research-market follistatin and ACE-031 vials have no human data.

Comparison table